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ABSTRACT BODY: 
Introduction or Background: The Sodium Iodide Symporter (NIS) is responsible for active transport of iodide
into thyroid follicular cells. The retention of its functional expression in most of the well-differentiated thyroid
carcinomas (DTCs) enables the use of radioactive iodine (RAI) for treatment of metastatic disease. Still, about
30% of patients with advanced forms of DTC became refractory to RAI which makes their management very
challenging. The main reason for impaired iodide uptake in refractory-DTC is the defective functional
expression of NIS. Several molecular players have been described as critical for TSH-induced NIS expression,
an example being the p38 mitogenic kinase. In breast cancer cells, the small GTPase RAC1 was shown to
mediate the positive impact of p38 kinase activity on NIS expression. We, on the other hand, have previously
shown that overexpression of RAC1b, a tumor-related splicing variant of RAC1, is associated with worse
outcomes in DTC and correlates with the MAPK-activating BRAFV600E mutation, which has been related to
the loss of NIS. Since RAC1 and RAC1b may act in an antagonistic fashion to regulate specific cellular
responses, we asked if RAC1b would be implicated in NIS downregulation observed in DTCs.
Methods Section (for Abstracts) or Case Presentation Section (Case Reports): NIS expression levels
were analyzed by RT-qPCR in a RAC1/RAC1b expression model system developed in non-transformed thyroid
cell lines. A non-radioactive iodide influx assay was used to confirm the impact of RAC1-signaling on the
efficacy of iodide uptake.
Results Section (Abstracts) or Discussion Section (Case Reports): We demonstrate that ectopic
overexpression of RAC1b is sufficient to decrease TSH-induced NIS expression, antagonizing the positive
effect of RAC1 GTPase. Moreover, we clearly document, for the first time in thyroid cells, that both NIS
expression and iodide uptake are downregulated upon RAC1 inhibition, supporting the role of canonical RAC1
signaling in promoting TSH-induced NIS expression.
Conclusion (Abstracts): Our findings provide evidence that RAC1 and RAC1b signaling are implicated in the
regulation of NIS expression in thyroid cells and suggest that RAC1b overexpression may be one of the
mechanisms contributing to the low levels of NIS observed in some subgroups of DTCs, antagonizing RAC1
stimulatory effect on the TSH/cAMP-mediated induction of NIS expression.
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